NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What does Rituxan deplete?

CD20 B cells
IL-1 receptors
TNF alpha
IL-6 receptors

The correct answer is: CD20 B cells

Rituxan is a medication that contains rituximab, a monoclonal antibody that targets and depletes B cells expressing the CD20 antigen on their surface. By binding to CD20, Rituxan induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, leading to the depletion of B cells. This action is beneficial in conditions where abnormal or overactive B cells are involved, such as certain types of lymphomas and autoimmune diseases like rheumatoid arthritis. Therefore, choice A is correct. The other options (B, C, and D) are incorrect: - IL-1 receptors are targeted by medications like anakinra, not Rituxan. - TNF alpha is targeted by drugs like adalimumab and infliximab, not Rituxan. - IL-6 receptors are targeted by medications like tocilizumab, not Rituxan.